Search

Your search keyword '"Gish, Robert G."' showing total 906 results
Start Over Author "Gish, Robert G."
906 results on '"Gish, Robert G."'

1. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

Author

Zhang, Huai, Targher, Giovanni, Byrne, Christopher D., Kim, Seung Up, Wong, Vincent Wai-Sun, Valenti, Luca, Glickman, Myer, Ponce, Jaime, Mantzoros, Christos S., Crespo, Javier, Gronbaek, Henning, Yang, Wah, Eslam, Mohammed, Wong, Robert J., Machado, Mariana Verdelho, Yu, Ming-Lung, Ghanem, Omar M., Okanoue, Takeshi, Liu, Jun-Feng, Lee, Yong-ho, Xu, Xiao-Yuan, Pan, Qiuwei, Sui, Meili, Lonardo, Amedeo, Yilmaz, Yusuf, Zhu, Li-Yong, Moreno, Christophe, Miele, Luca, Lupsor-Platon, Monica, Zhao, Lei, LaMasters, Teresa LeAnn, Gish, Robert G., Zhang, Huijie, Nedelcu, Marius, Chan, Wah Kheong, Xia, Ming-Feng, Bril, Fernando, Shi, Jun-Ping, Datz, Christian, Romeo, Stefano, Sun, Jian, Liu, Dan, Sookoian, Silvia, Mao, Yi-Min, Méndez-Sánchez, Nahum, Wang, Xiao-Yan, Pyrsopoulos, Nikolaos T., Fan, Jian-Gao, Fouad, Yasser, Sun, Dan-Qin, Giannini, Cosimo, Chai, Jin, Xia, Ze-Feng, Jun, Dae Won, Li, Guo-Jing, Treeprasertsuk, Sombat, Li, Ying-Xu, Cheung, Tan To, Zhang, Faming, Goh, George Boon-Bee, Furuhashi, Masato, Seto, Wai-Kay, Huang, Hui, Di Sessa, Anna, Li, Qing-Hong, Cholongitas, Evangelos, Zhang, Le, Silveira, Themis Reverbel, Sebastiani, Giada, Adams, Leon A., Chen, Wei, Qi, Xiaolong, Rankovic, Ivan, De Ledinghen, Victor, Lv, Wen-Jie, Hamaguchi, Masahide, Kassir, Radwan, Müller-Wieland, Dirk, Romero-Gomez, Manuel, Xu, Ying, Xu, Yi-Cong, Chen, Shi-Yao, Kermansaravi, Mohammad, Kuchay, Mohammad Shafi, Lefere, Sander, Parmar, Chetan, Lip, Gregory Y. H., Liu, Chun-Jen, Åberg, Fredrik, Lau, George, George, Jacob, Sarin, Shiv Kumar, Zhou, Jing-Ya, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

2. Demonstration of a population-based HCV serosurvey in Ho Chi Minh City, Viet Nam: Establishing baseline prevalence of and continuum of care for HCV micro-elimination by 2030

Author

Kim, Thanh V, Le, Duc H, Dao, Diem VB, Pham, Trang Ngoc Doan, Mize, Gary W, Phan, Loc TB, Nguyen, Dan X, Ngo, Thi-Thuy-Dung, Gish, Robert G, Lee, William M, Trang, Amy, Le, Anh N, Chen, Moon, Phan, Hai T, Nguyen, Binh T, Tang, Hong K, and Dao, Doan Y

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Infectious Diseases, Liver Disease, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis - C, Clinical Research, Emerging Infectious Diseases, Hepatitis, Good Health and Well Being, Hepatitis C virus, Ho Chi Minh City, Viet Nam, Framework, Micro-elimination, National elimi-nation, 2030, Access to care, HCV screening, HCV baseline linkage to care, National elimination, Clinical sciences, Health services and systems, Public health
Abstract

BackgroundA baseline of hepatitis C virus (HCV) burden and other HCV epidemiological profiles is necessary for HCV micro-elimination in Ho Chi Minh City (HCMC), Viet Nam. This study aimed to determine HCV exposure and prevalence of HCV viremia as well as the proportion of HCV testing and treatment uptake among participants.MethodsFrom 2019 to 2020, the probability proportionate to size sampling method was deployed to representatively invite approximately 20,000 adults (18 or older) throughout HCMC to free screening and linkage to care for HCV.FindingsIn HCMC, the weighted prevalence of anti-HCV was 1·3% (95% CI, 1·1%-1·6%). Individuals born from 1945 to 1964 had the anti-HCV prevalence of 3·6% (95% CI, 3·0%-4·2%) and represented 40·4% of all HCV cases. There were wide variations in anti-HCV prevalence in HCMC, including variations between districts, risk factors, and socioeconomic statuses. A baseline HCV continuum of care for the city demonstrated that only 28·5% (85/298, 95%CI 23·4-33·7%) of persons with anti-HCV (+) were aware of their HCV status, with 77.6% (66/85, 95%CI 68·8-86·5%) diagnosing HCV incidentally, 82·7% (62/75, 95%CI 74·1-91·2%) initiating anti-HCV therapy, and 53.6% (30/56, 95%CI 40·5-66·6%) achieving HCV cures.InterpretationThere remains a considerable disease burden of HCV in HCMC of which a significant proportion was in the age group born between 1945 to 1964. Additionally, there were significant gaps in HCV awareness, screening, and access to care in the community in Viet Nam. Thus, future interventions must have pragmatic targets, be tailored to the local needs, and emphasise screening.FundingThis work was supported by investigator-sponsored research grants from Gilead Sciences Inc. (Grant No: IN-US-987-5382); Roche Diagnostic International Ltd. (Grant No. SUB-000196); and in-kind donations from Abbott Diagnostic Viet Nam; Hepatitis B Foundation; Medic Medical Center, Viet Nam; Johns Hopkins University School of Medicine's Center of Excellence for Liver Disease in Viet Nam; and the Board of Directors, Viet Nam Viral Hepatitis Alliance (V-VHA).

Published
2022

3. A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma

Author

Lin, Nan, Lin, Yongping, Xu, Jianfeng, Liu, Dan, Li, Diange, Meng, Hongyu, Gallant, Maxime A, Kubota, Naoto, Roy, Dhruvajyoti, Li, Jason S, Gorospe, Emmanuel C, Sherman, Morris, Gish, Robert G, Abou‐Alfa, Ghassan K, Nguyen, Mindie H, Taggart, David J, Van Etten, Richard A, Hoshida, Yujin, and Li, Wei

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Rare Diseases, Cancer, Genetics, Prevention, Clinical Research, Liver Disease, Liver Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Carcinoma, Hepatocellular, Cell-Free Nucleic Acids, Early Detection of Cancer, Hematologic Tests, Humans, Liver Neoplasms, Prospective Studies, alpha-Fetoproteins, Clinical sciences
Abstract

The limited performance of guideline-recommended abdominal ultrasound and serum alpha-fetoprotein (AFP) highlights the urgent, unmet need for new biomarkers for more accurate detection of early hepatocellular carcinoma (HCC). To this end, we have conducted a prospective clinical validation study to evaluate the performance of the HelioLiver Test, a multi-analyte blood test combining cell-free DNA methylation patterns, clinical variables, and protein tumor markers. A blinded, multicenter validation study was performed with 247 subjects, including 122 subjects with HCC and 125 control subjects with chronic liver disease. The performance of the HelioLiver Test was compared with AFP and the GALAD score as established HCC surveillance blood tests. The performance of the HelioLiver Test (area under the receiver operating characteristic curve [AUROC] = 0.944) was superior to both AFP (AUROC = 0.851; p < 0.0001) and GALAD (AUROC = 0.899; p < 0.0001). Using a prespecified diagnostic algorithm, the HelioLiver Test showed sensitivities of 85% (95% confidence interval [CI], 78%-90%) for HCC of any stage and 76% (95% CI, 60%-87%) for early stage (American Joint Committee on Cancer [AJCC] I and II) HCC. In contrast, AFP (≥20 ng/mL) alone and the GALAD score (≥-0.63) showed lower sensitivities of 62% (95% CI, 54%-70%) and 75% (95% CI, 67%-82%) for HCC overall, and 57% (95% CI, 40%-71%) and 65% (95% CI, 49%-79%) for early stage (AJCC I and II) HCC, respectively. The specificities of the HelioLiver Test (91%; 95% CI, 85%-95%), AFP (97%; 95% CI, 92%-99%), and the GALAD score (94%; 95% CI, 88%-97%) were similar for control subjects. The HelioLiver Test showed superior performance for HCC detection compared to with both AFP and the GALAD score and warrants further evaluation in HCC surveillance settings.

Published
2022

7. Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States

Author

Toumi, Mondher, Wallace, Jack, Cohen, Chari, Marshall, Chris, Kitchen, Helen, Macey, Jake, Pegram, Hannah, Slagle, Ashley F., Gish, Robert G., Ning, Qin, Yatsuhashi, Hiroshi, Cornberg, Markus, Brunetto, Maurizia, van Bömmel, Florian, Xie, Qing, Lee, Dee, Habuka, Noriyuki, Sbarigia, Urbano, Beumont-Mauviel, Maria, Keever, Angelina Villasis, Takahashi, Yasushi, Lu, Yiwei, Liu, Ao, Chen, Qiaoqiao, Ito, Tetsuro, Radunz, Olaf, Puggina, Anna, Hilgard, Gudrun, Chan, Eric K.H., and Wang, Su

Published
2024
Full Text
View/download PDF

17. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

Author

Razavi, Homie A., Buti, Maria, Terrault, Norah A., Zeuzem, Stefan, Yurdaydin, Cihan, Tanaka, Junko, Aghemo, Alessio, Akarca, Ulus S., Al Masri, Nasser M., Alalwan, Abduljaleel M., Aleman, Soo, Alghamdi, Abdullah S., Alghamdi, Saad, Al-Hamoudi, Waleed K., Aljumah, Abdulrahman A., Altraif, Ibrahim H., Asselah, Tarik, Ben-Ari, Ziv, Berg, Thomas, Biondi, Mia J., Blach, Sarah, Braga, Wornei S.M., Brandão-Mello, Carlos E., Brunetto, Maurizia R., Cabezas, Joaquin, Cheinquer, Hugo, Chen, Pei-Jer, Cheon, Myeong-Eun, Chuang, Wan-Long, Coffin, Carla S., Coppola, Nicola, Craxi, Antonio, Crespo, Javier, De Ledinghen, Victor, Duberg, Ann-Sofi, Etzion, Ohad, Ferraz, Maria Lucia G., Ferreira, Paulo R.A., Forns, Xavier, Foster, Graham R., Gaeta, Giovanni B., Gamkrelidze, Ivane, García-Samaniego, Javier, Gheorghe, Liliana S., Gholam, Pierre M., Gish, Robert G., Glenn, Jeffrey, Hercun, Julian, Hsu, Yao-Chun, Hu, Ching-Chih, Huang, Jee-Fu, Janjua, Naveed, Jia, Jidong, Kåberg, Martin, Kaita, Kelly D.E., Kamal, Habiba, Kao, Jia-Horng, Kondili, Loreta A., Lagging, Martin, Lázaro, Pablo, Lazarus, Jeffrey V., Lee, Mei-Hsuan, Lim, Young-Suk, Marotta, Paul J., Navas, Maria-Cristina, Naveira, Marcelo C.M., Orrego, Mauricio, Osiowy, Carla, Pan, Calvin Q., Pessoa, Mário G., Raimondo, Giovanni, Ramji, Alnoor, Razavi-Shearer, Devin M., Razavi-Shearer, Kathryn, Ríos-Hincapié, Cielo Y., Rodríguez, Manuel, Rosenberg, William M.C., Roulot, Dominique M., Ryder, Stephen D., Safadi, Rifaat, Sanai, Faisal M., Santantonio, Teresa A., Sarrazin, Christoph, Shouval, Daniel, Tacke, Frank, Tergast, Tammo L., Villalobos-Salcedo, Juan Miguel, Voeller, Alexis S., Yang, Hwai-I, Yu, Ming-Lung, and Zuckerman, Eli

Published
2023
Full Text
View/download PDF

20. Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Author

Jones, David EJ, primary, Beuers, Ulrich, additional, Bonder, Alan, additional, Carbone, Marco, additional, Culver, Emma, additional, Dyson, Jessica, additional, Gish, Robert G, additional, Hansen, Bettina E, additional, Hirschfield, Gideon, additional, Jones, Rebecca, additional, Kowdley, Kris, additional, Kremer, Andreas E., additional, Lindor, Keith, additional, Mayo, Marlyn, additional, Mells, George, additional, Neuberger, James, additional, Prince, Martin, additional, Swain, Mark, additional, Tanaka, Atsushi, additional, Thorburn, Douglas, additional, Trauner, Michael, additional, Trivedi, Palak, additional, Weltman, Martin, additional, Yeoman, Andrew, additional, and Levy, Cynthia, additional

Published
2024
Full Text
View/download PDF

21. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB

Author

Yuen, Man-Fung, Locarnini, Stephen, Lim, Tien Huey, Strasser, Simone I., Sievert, William, Cheng, Wendy, Thompson, Alex J., Given, Bruce D., Schluep, Thomas, Hamilton, James, Biermer, Michael, Kalmeijer, Ronald, Beumont, Maria, Lenz, Oliver, De Ridder, Filip, Cloherty, Gavin, Ka-Ho Wong, Danny, Schwabe, Christian, Jackson, Kathy, Lai, Ching Lung, Gish, Robert G., and Gane, Edward

Published
2022
Full Text
View/download PDF

24. Markov modeling in hepatitis B screening and linkage to care

Author

Sehr, Martin A, Joshi, Kartik D, Fontanesi, John M, Wong, Robert J, Bitmead, Robert R, and Gish, Robert G

Subjects
Biological Sciences, Chronic Liver Disease and Cirrhosis, Clinical Research, Health Services, Infectious Diseases, Hepatitis, Digestive Diseases, Emerging Infectious Diseases, Liver Disease, Cancer, Good Health and Well Being, Computer Simulation, Hepatitis B, Humans, Markov Chains, Mass Screening, Models, Biological, Patient Care, Point-of-Care Systems, Hepatitis B virus, Screening, Markov modeling, Point-of-care, Standard-of-care, Testing, Bioinformatics, Biological sciences
Abstract

BackgroundWith up to 240 million people chronically infected with hepatitis B worldwide, including an estimated 2 million in the United States, widespread screening is needed to link the infected to care and decrease the possible consequences of untreated infection, including liver cancer, cirrhosis and death. Screening is currently fraught with challenges in both the developed and developing world. New point-of-care tests may have advantages over standard-of-care tests in terms of cost-effectiveness and linkage to care. Stochastic modeling is applied here for relative utility assessment of point-of-care tests and standard-of-care tests for screening.MethodsWe analyzed effects of point-of-care versus standard-of-care testing using Markov models for disease progression in individual patients. Simulations of large cohorts with distinctly quantified models permitted the assessment of particular screening schemes. The validity of the trends observed is supported by sensitivity analyses for the simulation parameters.ResultsIncreased utilization of point-of-care screening was shown to decrease hepatitis B-related mortalities and increase life expectancy at low projected expense.ConclusionsThe results suggest that standard-of-care screening should be substituted by point-of-care tests resulting in improved linkage to care and decrease in long-term complications.

Published
2017

25. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature

Author

Lonardo, Amedeo, primary, Bril, Fernando, additional, Caldwell, Stephen H., additional, Eslam, Mohammed, additional, Fan, Jian-Gao, additional, Gish, Robert G., additional, Gronbaek, Henning, additional, Sanal, Madhusudana Girija, additional, Stefan, Norbert, additional, Suzuki, Ayako, additional, Targher, Giovanni, additional, Tilg, Herbert, additional, Yu, Ming-Lung, additional, Zheng, Ming-Hua, additional, and George, Jacob, additional

Published
2024
Full Text
View/download PDF

43. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Author

Wranke, A., Pinheiro Borzacov, L.M., Lobato, C., Hamid, S., Ceausu, E., Dalekos, G.N., Turcanu, A., Niro, G.A., Lubna, F., Abbas, M., Ingiliz, P., Ferenci, P., Vanwolleghem, T., Hayden, T., Dashdorj, N., Motoc, A., Hardtke, S., Yurdaydin, Cihan, Abbas, Zaigham, Buti, Maria, Cornberg, Markus, Esteban, Rafael, Etzion, Ohad, Gane, Edward J., Gish, Robert G., Glenn, Jeffrey S., Hamid, Saeed, Heller, Theo, Koh, Christopher, Lampertico, Pietro, Lurie, Yoav, Manns, Michael, Parana, Raymundo, Rizzetto, Mario, Urban, Stephan, and Wedemeyer, Heiner

Published
2019
Full Text
View/download PDF

46. Strategies to eliminate hepatitis C virus infection in the Americas

Author

Diaz, Luis Antonio, primary, García, Sergio, additional, Khan, Rayan, additional, Ayares, Gustavo, additional, Monasterio, Javier Uribe, additional, Idalsoaga, Francisco, additional, Fuentes, Eduardo, additional, Medel, María Paz, additional, Ramirez, Carolina, additional, Lazo, Mariana, additional, Ferreccio, Catterina, additional, Mendizabal, Manuel, additional, Dirchwolf, Melisa, additional, Guerra, Patricia, additional, Oliveira, Claudia, additional, Pessoa, Mário, additional, Álvares-da-Silva, Mario, additional, Sebastiani, Giada, additional, Brahmania, Mayur, additional, Ramji, Alnoor, additional, Niazi, Mina, additional, Ko, Hin HIn, additional, Feld, Jordan J., additional, Restrepo, Juan Carlos, additional, Ramirez, Wagner, additional, Alfaro, Omar, additional, Castellanos-Fernández, Marlen, additional, Carrera, Enrique, additional, Aguirre, Jose Roberto, additional, Maldonado Cardona, Katherine Emilia, additional, Sanchez, Abel, additional, Sánchez, Marco, additional, Andara, Maria Teresa, additional, Castro-Narro, Graciela, additional, Chávez-Tapia, Norberto Carlos, additional, Méndez-Sánchez, Nahum, additional, Adames, Enrique, additional, Lombardo, Julissa, additional, Girala, Marcos, additional, Morán, Elias, additional, Padilla, P. Martin, additional, Diaz-Ferrer, Javier, additional, Tagle, Martin, additional, Mainardi, Victoria, additional, Hernandez, Nélia, additional, Martinez, Edmundo, additional, Alvarado-Tapias, Edilmar, additional, Robert, Leon, additional, Hernandez-Tejero, Maria, additional, De Sicilia, Mauricio Garcia Saenz, additional, Zhang, Wei, additional, Bajaj, Jasmohan S., additional, Tapper, Elliot, additional, Izzy, Manhal, additional, Gish, Robert G., additional, Attar, Bashar, additional, Cotter, Thomas, additional, Kamath, Patrick S., additional, Singal, Ashwani, additional, Bataller, Ramon, additional, Mezzano, Gabriel, additional, Soza, Alejandro, additional, Lazarus, Jeffrey, additional, Arrese, Marco, additional, and Arab, Juan Pablo, additional

Published
2023
Full Text
View/download PDF

48. Self-stigma in chronic hepatitis B: content and psychometric validation of a new patient-reported outcome instrument

Author

Gish, Robert G., primary, Toumi, Mondher, additional, Wallace, Jack, additional, Cohen, Chari, additional, Wang, Su, additional, Marshall, Chris, additional, Kitchen, Helen, additional, Macey, Jake, additional, Pegram, Hannah, additional, Houts, Carrie, additional, Mangrum, Rikki, additional, Slagle, Ashley F., additional, Lazarus, Jeffrey, additional, Kennedy, Patrick, additional, van Bömmel, Florian, additional, Brunetto, Maurizia, additional, Ning, Qin, additional, Yatsuhashi, Hiroshi, additional, Cornberg, Markus, additional, Xie, Qing, additional, Lee, Dee, additional, Keever, Angelina Villasis, additional, Sbarigia, Urbano, additional, Takahashi, Yasushi, additional, Jerzorwski, John, additional, Talloen, Willem, additional, Biermer, Michael, additional, and Chan, Eric, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results